According to the International Agency for Research on Cancer, stomach cancer was the fourth most common malignancy and the second leading cause of cancer death in the world in 2008, with an estimated 990,000 new cases and about 738,000 deaths. Approximately 72% of new cases occurred in developing countries.
M. Elena Martinez, PhD, Arizona Cancer Center Prevention and Control program co-leader and co-director of the Cancer Health Disparities Institute, is a co-author on H. Pylori Drug Study published in the Lancet. A study more than five years in the making finally has the go-ahead to get under way, thanks in large part to funding from the Bill and Melinda Gates Foundation. The study, which was designed by researchers from the Arizona Cancer Center and the Southwest Oncology Group, hopes to discover a reliable and widely applicable method for the prevention and gradual reduction of gastric cancer in Latin America.
In developed countries, such as the US., gastric cancer cases have been reduced by 90 % since the early nineteenth century. A few years ago, representatives from seven countries met in Antigua, Guatemala, to plan the necessary steps for the management of H. pylori in Latin America. The first step is a pilot study to find the best approach for the treatment of H. pylori infection. A larger study will begin after the pilot study to monitor the affects of the chosen treatment on the incidence of gastric cancer in Latin America.
You can see the news story through the Arizona Cancer Center’s website – http://azcc.arizona.edu/node/3787